Trials / Completed
CompletedNCT07007091
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants
A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Bioavailability of Risankizumab Subcutaneous Administration With On-Body Injector Relative to Prefilled Syringe
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 260 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous administration with an on-body injector relative to a prefilled syringe
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risankizumab | Subcutaneous (SC) Injection |
| DRUG | Risankizumab | On-Body Injector (OBI) |
Timeline
- Start date
- 2025-06-12
- Primary completion
- 2026-01-15
- Completion
- 2026-01-15
- First posted
- 2025-06-05
- Last updated
- 2026-01-27
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07007091. Inclusion in this directory is not an endorsement.